Active Ingredient History
Evogliptin is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs. It was developed by the South Korean pharmaceutical company Dong-A ST and is approved for use in South Korea and Russia. In a meta-analysis involving data from 6 randomized controlled trials, Dutta et. al. demonstrated the good glycaemic efficacy and safety of this medicine as compared to other DPP4 inhibitors like sitagliptin and linagliptin. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Albuminuria (Phase 2)
Aortic Valve Disease (Phase 2/Phase 3)
Bone Diseases, Metabolic (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Endocrine System Diseases (Phase 4)
Healthy Volunteers (Phase 1)
Hemodialysis, Home (Phase 1)
Hepatitis B, Chronic (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 1)
Liver Cirrhosis (Phase 4)
Liver Diseases (Phase 1)
Metabolic Diseases (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 4)
Osteoporosis (Phase 4)
Renal Insufficiency (Phase 2)
Vas Deferens (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue